- Home
- PRQR vs GALT Comparison
PRQR vs GALT Comparison
Compare PRQR & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | GALT |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.5M | 199.2M |
| IPO Year | 2014 | 2008 |
Fundamental Metrics
Financial Performance| Metric | PRQR | GALT |
|---|---|---|
| Price | $1.50 | $2.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $7.25 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 566.6K | 336.2K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $1.28 |
| 52 Week High | $3.10 | $7.13 |
Technical Indicators
Market Signals| Indicator | PRQR | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 45.99 |
| Support Level | $1.37 | $2.09 |
| Resistance Level | $1.58 | $2.60 |
| Average True Range (ATR) | 0.11 | 0.22 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 53.45 | 22.60 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.